SCM
BLTE

Squadron Capital Management’s Belite Bio BLTE Stock Holding History

Squadron Capital Management’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,000
Closed -$4.16M – 39
2025
Q4 		$4.16M Buy
+26,000
New +$3.08M 1.76% 19

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Squadron Capital Management's BLTE Position: Q1 2026 in Review

Squadron Capital Management sold out of Belite Bio (BLTE) in Q1 2026, closing a stake of 26,000 shares — an estimated $4.16M sold.

Squadron Capital Management first reported a position in BLTE in Q4 2025 and held it in 1 quarter. The position peaked at $4.16M in Q4 2025. 75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

  • Squadron Capital Management reported no remaining Belite Bio position as of Q1 2026 after selling out during the quarter.
  • Squadron Capital Management sold 26,000 Belite Bio shares in Q1 2026, an estimated $4.16M.
  • Squadron Capital Management first reported a position in Belite Bio in Q4 2025 and held it in 1 quarter.
  • Squadron Capital Management's Belite Bio position peaked at $4.16M in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on Squadron Capital Management's 13F filing for Q1 2026, filed 15 May 2026.